X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SmithKline: Fast recovery expected - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 20, 2001

    SmithKline: Fast recovery expected

    SmithKline Beecham Pharma (SKBP) had a tough time last year. Additional Import duties imposed on one of its key product, Energix-B coupled with price cuts in other key products such as Zevit impacted the performance of the company negatively. Further, increasing competition from domestic manufacturers resulted in falling realisations in vaccines, where the company has a stronghold. However, we expect the company to bounce back with new products launches and variants expected to help in quick revival of its fortunes. Read on.

    It all started with government’s decision to impose 38.5% import duty on Hepatitis B vaccine. Thus, Energix B (the company’s product for Hepatitis B), which was imported by SKBP from its parent company suffered from this duty hike. To make things worse, inclusion of the vaccine in Mass Immunization programme initiated entry of other established players like Wockhardt, Pfizer, and Shantha Biotech in the segment. The competition amongst the players led to aggressive price cuts and growth for the product became volume driven. Energix B thus suffered heavily as it was priced at the premium end.

    To counter this situation, SKBP launched a range of stand alone and multi-clonal vaccines as shown in the table below. The combinational vaccine is expected to canabalise usage of various standalone vaccines and is expected to receive good response in the market place. We expect new vaccine launches, combinational vaccines in particular to compensate for drop in sales of Energix B.

    SKBP- Vaccine Product Portfolio
    Product Remarks
    Harvix Hepatitis A Vaccine launched last year
    Viralrix Chickenpox Vaccine launched last year
    Energix B Existing product for Hepatitis B vaccine
    Typherix Vaccine for typhoid launched last year
    Twinrix Combinational vaccine for Hepatitis A and B
    Tritanrix Combinational vaccine for Hepatitis B and DTP
    Infranrix Launch expected soon

    Apart from vaccines, SKBP’s portfolio includes Iodex (and line extensions of Iodex brand for pain management), Augmentin (fast growing brand in anti-infective segment), Zevit and Fefol (leading nutritional products). Except for the nutritional products, all other brands are out of DPCO coverage. We expect these brands to register growth in the range of 10-15% in the current year. However, the vaccine portfolio remains the trump card for SKBP’s success. Based on success of its new vaccine introduction, we expect the company to register a growth of 10.5% in FY02 (as shown in the chart above).

    The Indian vaccine market is lucrative and volumes are expected to grow at 35% p.a. Considering that, one can expect further product launches in vaccine segment to continue based on the fact that its parent company is the largest player in vaccine segment worldwide. However, the concern for the company is fact that these vaccines are currently, imported by SKBP from the parent company to market it in the local market. In a scenario where the market is highly susceptible to price wars, heavy import duty remains a cause of concern.

    SKBP remains at the mercy of its parent company…
    Another cause of concern for investors at this point of time is the complex nature of parent company’s holdings. In line with the global merger, Glaxo India and SKBP have announced their merger plans in the ratio of 2:1 (1 share of Glaxo for every two shares of SKBP). The merger is expected to create synergies in terms of operations and better distribution reach resulting in considerable cost-savings for the merged entity. After, the merger, the parent company would still have another subsidiary Burroughs Wellcome in India.

    Apart from that, erstwhile SmithKline Beecham (SB) also had a 100% subsidiary viz. SmithKline Beecham Asia. ‘Hibrix’, a meningitis vaccine was launched by the parent company through this subsidiary. There is an uncertainty as to the launch of ‘Avandia’ an important advancement in treatment of Type 2 diabetes. In such a scenario future prospects of SKBP, which is at the mercy of parent’s product portfolio, remains uncertain.

    SKBP earns service income from maintaining, providing and analyzing clinical data from erstwhile SB. Though the prospects of the same, increasing in future are bright, there is uncertainty on the same.

    At the current market price of Rs 170, the stock is trading at 14.5 times it FY02E earnings. The valuations of the company are quite low when compared to other MNC peers. It could be due to the fact that the markets are adopting a wait and watch approach. Apart from that, the stock price of the company is moving exactly in tandem with the swap ratio with Glaxo (330 / 2) and is mirroring the recent southward journey in Glaxo’s stock.

     

     

    Equitymaster requests your view! Post a comment on "SmithKline: Fast recovery expected". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    TRACK SMITHKLINE PHARMA

    • Track your investment in SMITHKLINE PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS